Marshall Urist - 05 Nov 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: EVP, Research & Investments
Signature: /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist
Issuer symbol: RPRX
Transactions as of: 05 Nov 2025
Transactions value $: $0
Form type: 4
Filing time: 07 Nov 2025, 16:16:29 UTC
Previous filing: 08 Aug 2025
Next filing: 03 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Urist Marshall	EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist	07 Nov 2025	0001838139

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+4.63K	+11.78%	$0.00	43.9K	05 Nov 2025	Direct	F1
transaction	RPRX	Class A Ordinary Shares	Conversion of derivative security	$0	+160K	+342.85%	$0.00	207K	07 Nov 2025	By Sandy Lamm LLC	F2
holding	RPRX	Class A Ordinary Shares						19K	05 Nov 2025	By IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPRX	LP interests in RPI US Partners 2019, LP	Conversion of derivative security	$0	-16K	-6.07%	$0.00	247K	07 Nov 2025	Class A Ordinary Shares	160K	$0.00	By Sandy Lamm LLC	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
F2	These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.
F3	Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.